Description
DE-OBLIGATE FUNDS BY -$55,139.00 TO CLOSE OUT. RADIOPHARMACEUTICALS EXERCISE OPTION YEAR FOUR
Base award description: RADIOPHARMACEUTICALS EXERCISE OPTION YEAR FOUR
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2017-10-01+$489,968= $489,968
- Mod P000012019-01-15-$55,139= $434,829
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2017-10-01 | +$489,968 | $489,968 | RADIOPHARMACEUTICALS EXERCISE OPTION YEAR FOUR |
| Mod P00001· FUNDING ONLY ACTION | 2019-01-15 | −$55,139 | $434,829 | DE-OBLIGATE FUNDS BY -$55,139.00 TO CLOSE OUT. RADIOPHARMACEUTICALS EXERCISE OPTION YEAR FOUR |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ZTPJLM54CAN3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24919N0063 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $102,389 | FY2019 |
| VA24917J2761 | 626-NASHVILLE (00626) · 6505 · DRUGS AND BIOLOGICALS | $411,685 | FY2017 |
| VA24916J3572 | 626-NASHVILLE (00626) · 6505 · DRUGS AND BIOLOGICALS | $283,942 | FY2016 |
| VA24915J3595 | 626-NASHVILLE · 6505 · DRUGS AND BIOLOGICALS | $260,127 | FY2015 |
| VA24914J1511 | 626-NASHVILLE · 6505 · DRUGS AND BIOLOGICALS | $116,003 | FY2014 |
| VA24914D0110 | 626-NASHVILLE (00626) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2014 |
Other recipients under 6505 from 626-NASHVILLE (00626) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24918F2128 | ABBVIE US LLC | 626-NASHVILLE (00626) | $8,874 | FY2018 |
| 36C24918N1818 | NEUROCRINE BIOSCIENCES, INC. | 626-NASHVILLE (00626) | $4,660 | FY2018 |
| 36C24918N1672 | ABBVIE US LLC | 626-NASHVILLE (00626) | $4,363 | FY2018 |
| 36C24918N1434 | GRIFOLS THERAPEUTICS LLC | 626-NASHVILLE (00626) | $12,807 | FY2018 |
| 36C24918N1404 | ABBVIE US LLC | 626-NASHVILLE (00626) | $8,874 | FY2018 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24918J2822_3600_VA24914D0110_3600 · retrieved 2026-09-26.